MSS Clinical Trials in Beijing, Beijing Municipality
5 recruitingBeijing, Beijing Municipality, China
Showing 1–5 of 5 trials
Recruiting
Phase 2
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Colorectal, CancerBRAF V600ESintilimab+4 more
Tianjin Medical University Cancer Institute and Hospital49 enrolled4 locationsNCT07506109
Recruiting
Phase 1Phase 2
Study of GV20-0251 in Participants With Solid Tumor Malignancies
MelanomaNon-small Cell Lung CancerSolid Tumor Cancer+6 more
GV20 Therapeutics350 enrolled3 locationsNCT07070518
Recruiting
A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
MSS Metastatic Colorectal CancersMSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Peking University Cancer Hospital & Institute50 enrolled1 locationNCT06549907
Recruiting
Phase 2
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Metastatic Colorectal CancerRAS MutationMSS
Beijing Hospital60 enrolled1 locationNCT06321081
Recruiting
Phase 2
XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer
Rectal CancerMSS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences92 enrolled1 locationNCT05815303